Share Email Print

Proceedings Paper

A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care
Author(s): Leanne F. Harris; Paul Rainey; Vanessa Castro-López; James S. O'Donnell; Anthony J. Killard
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Millions of patients worldwide are receiving anticoagulant therapy to treat hypercoagulable diseases. While standard testing is still performed in the central laboratory, point-of-care (POC) diagnostics are being developed due to the increasing number of patients requiring long-term anticoagulation and with a need for more personalized and targeted therapy. Many POC devices on the market focus on clot measurement, a technique which is limited in terms of variability, highlighting the need for more reliable assays of anticoagulant status. The anti-Xa assay, a factor specific optical assay, was developed to measure the extent to which exogenous factor Xa (FXa) is inhibited by heparinantithrombin complexes. We have developed a novel microfluidic device and assay for monitoring the effect of heparin anticoagulant therapy at the point-of-care. The assay which was also developed in our institute is based on the anti-Xa assay principle but uses fluorescence as the method of detection. Our device is a disposable laminate microfluidic strip, fabricated from the cyclic polyolefin (COP), Zeonor®, which is extremely suitable for application to fluorescent device platforms. We present data on the execution of the anti-Xa assay in this microfluidic format, demonstrating that the assay can be used to measure heparin in human plasma samples from 0 to 0.8 U/ml, with average assay reproducibility of 8% and a rapid result obtained within 60 seconds. Results indicate that with further development, the fluorogenic anti-Xa assay and device could become a successful method for monitoring anticoagulant therapy.

Paper Details

Date Published: 28 May 2013
PDF: 8 pages
Proc. SPIE 8765, Bio-MEMS and Medical Microdevices, 876509 (28 May 2013); doi: 10.1117/12.2016872
Show Author Affiliations
Leanne F. Harris, Dublin City Univ. (Ireland)
Paul Rainey, Dublin City Univ. (Ireland)
Vanessa Castro-López, Dublin City Univ. (Ireland)
James S. O'Donnell, Trinity College Dublin (Ireland)
St. James’s Hospital (Ireland)
Anthony J. Killard, Dublin City Univ. (Ireland)
Univ. of the West of England (United Kingdom)

Published in SPIE Proceedings Vol. 8765:
Bio-MEMS and Medical Microdevices
Angeliki Tserepi; Manuel Delgado-Restituto; Eleni Makarona, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?